Wegovy Pill vs Orforglipron (Foundayo): Which Oral GLP-1 Should You Take in 2026?

Two oral GLP-1 options, two very different daily routines. Both FDA-approved for weight loss in 2026.

Wegovy Pill vs Foundayo: The Quick Comparison (April 2026)

Before we get into the details, here's the full picture in one table. We built this from FDA prescribing information, published clinical trial results, and official manufacturer pricing pages — not from blog posts rewriting blog posts.

Sources: OASIS 4 trial (NEJM, Sept 2025), ATTAIN-1 trial (Lilly FDA filing, 2026), Wegovy prescribing information, Foundayo prescribing information, NovoCare pricing page, LillyDirect pricing page. These were separate trials, not head-to-head. Pricing verified April 4, 2026.

9 Real Differences Between Wegovy Pill and Foundayo

The table above covers everything. But here are the 9 differences that actually drive the decision — not the ones that look good in a bullet list but don't change what you do.

1. Weight loss: Wegovy pill wins on the numbers.

Roughly 14% vs 11% average weight loss in their respective obesity trials. That gap is clinically meaningful — for a 235-lb person, it's roughly 7 extra pounds, which compounds with every month of consistent use.

2. Dosing freedom: Foundayo wins by a mile.

Any time of day. With food or without. No water limits. Versus the Wegovy pill's strict morning-on-an-empty-stomach requirement. If you've ever missed a dose because life got in the way, this matters more than any trial number.

3. Cardiovascular protection: Wegovy pill, and it's not close right now.

FDA-approved label for reducing heart attack, stroke, and cardiovascular death in adults with established heart disease. Foundayo's CV trials haven't finished yet.

4. Real-world track record: Wegovy pill has a 3-month head start.

More than 600,000 prescriptions have been written since January. Prescribers know it. Pharmacies stock it. Insurance is figuring it out. Foundayo launched April 6 — it's legitimately brand new.

5. Birth control interaction: Foundayo has a warning, Wegovy pill doesn't.

If you're on oral contraceptives, Foundayo may reduce their effectiveness. That's a concrete decision factor for millions of women.

6. Drug interactions: Foundayo is more complex.

CYP3A4 interactions and a simvastatin cap don't apply to everyone. But if they apply to you, they could narrow or eliminate Foundayo as an option.

7. Pricing: Effectively a draw at the pharmacy counter.

$149/month starting dose. ~$299/month maintenance dose for both. The differences are in the fine print: promo expiration dates, refill timing requirements, and Medicare pathways.

8. List price: Foundayo is cheaper for the healthcare system.

$649/month WAC vs $1,349/month. This matters for insurance negotiations and formulary placement, which may affect your long-term access and copay stability.

9. Manufacturing scalability: Foundayo has a structural advantage.

As a small molecule (not a peptide), it's simpler and cheaper to produce at scale. No cold-chain storage required. Over time, this could translate to better availability and potentially lower prices — though that's forward-looking, not a guarantee today.

Who Should Choose Wegovy Pill — and Who Should Choose Foundayo Instead?

The clinical data gives the Wegovy pill a measurable edge on weight loss. But clinical data doesn't know what your mornings look like. The right oral GLP-1 is the one you'll actually take correctly for a year — not the one that wins a spreadsheet contest you'll never see.

The best pill is the one you can take correctly and consistently.

Pick Wegovy pill if:

You want the strongest current obesity-specific evidence. The OASIS 4 trial showed 13.6% average weight loss in an obesity population — a trial designed to test this exact use case. Foundayo's ATTAIN-1 trial showed 11.1%. That gap is real, and for some people, an extra 2–3% of body weight lost is the difference between dropping two sizes and dropping one.

You have known heart disease. The Wegovy pill is currently the only oral GLP-1 with an FDA-approved indication for reducing heart attack, stroke, and cardiovascular death risk in adults with established cardiovascular disease plus obesity or overweight. If your cardiologist is part of this conversation, this may be the deciding factor.

You can handle the morning routine. If you already wake up, scroll your phone for 30 minutes, and eat later — the fasting requirement slots right in. Plenty of Wegovy pill users report it's barely an adjustment. Some even set an alarm earlier, take the pill, go back to sleep, and eat when they get up.

You're already on injectable Wegovy. Same active ingredient (semaglutide). Your prescriber can transition you directly. You know the side effects, you know it works for your body, and you're just ditching the needle.

You take oral contraceptives. Foundayo's label warns it may reduce the effectiveness of birth control pills and recommends backup contraception for 30 days after starting and after each dose increase. The Wegovy pill doesn't carry that warning.

Pick Foundayo if:

Your mornings are genuinely unpredictable. Shift work. Rotating schedules. Travel across time zones. A toddler who doesn't care about your medication timing. If the Wegovy pill's 30-minute fasting window would realistically cause you to skip doses or take the pill wrong, Foundayo's flexibility becomes a clinical advantage, not just a convenience perk.

You take other morning medications. The Wegovy pill says wait 30 minutes before taking other oral meds. If you're on a blood pressure medication, thyroid med, or anything else that's already competing for your empty stomach, Foundayo simplifies that equation.

Adherence has been a problem for you before. Maybe you've started medications and forgotten them, or you've tried regimens with timing restrictions and they fell apart by month two. Dr. Catherine Varney, obesity medicine director at UVA Health, told NPR she wouldn't be surprised if Foundayo patients lose more weight in practice — because it's harder to take wrong. In GLP-1 therapy, the best medication is the one you actually take consistently.

You want to start an oral GLP-1 and Foundayo's pricing or coverage works better for your situation. Lilly says eligible Medicare Part D patients may pay ~$50/month as early as July 2026. If that applies to your situation, it's worth checking.

Pick neither oral pill if:

You want the absolute maximum weight loss and don't mind needles. The injectable versions — Wegovy injection and Zepbound — still produce the highest average weight loss (roughly 15–17%+). The oral pills are genuinely effective, but they're the entry point, not the ceiling.

We have a full injectable GLP-1 comparison guide if that's where you land.

The Honest Version (Before We Go Deeper)

We're about to walk you through weight loss data, pricing tables, side effects, and access details. Before we do, here's what we'd tell you if we were sitting across from you:

Neither of these pills is as powerful as the injectable versions. If maximum weight loss is your only priority and you're fine with needles, the weekly injections (Wegovy injection, Zepbound) still win that contest. The pills exist for people who don't want needles, want a lower-cost entry point, or want the convenience of a daily tablet they can pick up at a pharmacy without cold storage. That's a massive category of people — but it's worth being straight about it.

The Wegovy pill does NOT offer the easiest daily routine. If you know — honestly — that coffee, breakfast, shift work, or other morning meds will make the fasting rules a mess, Foundayo is the more realistic oral fit. But because the Wegovy pill is already well-established, has stronger current obesity-specific data, and adds a cardiovascular indication, it remains the better choice for the majority of people who can manage a structured morning.

How Much Weight Will You Actually Lose? The Trial Data, Labeled Properly

Weight loss percentages get thrown around in headlines without much context, so let's do this right. These two pills were tested in separate trials, in somewhat different populations, using slightly different measurements. Comparing them requires labels.

Wegovy Pill — OASIS 4 Trial Results

The OASIS 4 trial studied oral semaglutide 25 mg in adults with obesity or overweight plus at least one weight-related health condition, without diabetes. The results at 64 weeks:

• 13.6% average weight loss — includes everyone regardless of whether they stayed on medication
• 16.6% average weight loss among patients who stayed on treatment the full 64 weeks
• 76% of participants achieved at least 5% weight loss
• 47% achieved 15%+ weight loss
• Average baseline body weight: ~235 lbs

This was published in the New England Journal of Medicine in September 2025. It's the strongest obesity-specific evidence for any oral GLP-1 medication.

Foundayo — ATTAIN-1 Trial Results

The ATTAIN-1 trial studied orforglipron (now Foundayo) in adults with obesity or overweight plus at least one weight-related condition. Results at 72 weeks for the highest dose:

• 11.1% average weight loss regardless of whether patients completed the trial
• 12.4% average weight loss among patients who stayed on treatment
• 71.8% achieved at least 5% weight loss at the highest dose
• Average starting weight: ~220 lbs

Important note: The clinical trials used 36 mg capsules; the FDA-approved tablets are 17.2 mg. Lilly states these are equivalent formulations.

So Wegovy Pill Wins on Weight Loss. Is It That Simple?

On paper, yes — approximately 2.5 percentage points more weight loss in an obesity population. That's clinically meaningful. For a 235-lb person, the difference between 14% and 11% is roughly 7 extra pounds — and those pounds compound with every month of consistent use.

But here's the nuance most pages skip: these were separate trials with different study designs and populations. We can compare them directionally, but treating the numbers as an exact head-to-head result would be dishonest. No one has run a head-to-head trial of these two pills in the same obesity population using the same protocol.

What About the ORION Study? (Why Novo Says Wegovy Wins)

Novo Nordisk released the ORION study at the Obesity Medicine Association conference in April 2026. It's a population-adjusted indirect treatment comparison — meaning they took data from the OASIS 4 and ATTAIN-1 trials and statistically adjusted them to make them comparable.

The results: oral semaglutide 25 mg showed 3.2 percentage points more weight loss than orforglipron 36 mg, and orforglipron showed roughly 14 times higher odds of patients stopping treatment due to GI side effects.

We report this because the numbers are significant. But we also want you to know: this was conducted by Novo Nordisk (who sells the Wegovy pill), it is not a head-to-head trial, and indirect comparisons have inherent limitations. Treat it as context, not gospel.

What About ACHIEVE-3? (Why Headlines Said Orforglipron “Beat” Semaglutide)

If you've seen headlines claiming orforglipron outperformed oral semaglutide, they're referencing ACHIEVE-3 — a trial published in The Lancet in February 2026. Important details most comparisons bury:

• It studied adults with type 2 diabetes — not an obesity-only population
• It compared orforglipron 36 mg against oral semaglutide 14 mg — that's the Rybelsus diabetes dose, not the Wegovy pill's 25 mg obesity dose
• In that specific matchup, orforglipron did produce more weight loss (19.7 lbs vs 11.0 lbs)

This trial tells us orforglipron is genuinely potent. But it doesn't prove orforglipron beats the actual Wegovy pill at its obesity dose. Different drug, different dose, different population.

Our evidence hierarchy for this page: Direct obesity trials > head-to-head diabetes trials > indirect company-funded comparisons > news summaries.

Which Pill Is Easier to Live With Every Day?

This is the single biggest real-world split between these two medications, and it's where most comparison pages give you a sentence when you need a paragraph.

Best choice depends on whether stricter routine or easier adherence matters more to you.

Wegovy Pill: The Morning Ritual

According to the prescribing information:

1. Take the Wegovy pill first thing in the morning on an empty stomach
2. Use up to 4 ounces of plain water only — no other beverages
3. Wait at least 30 minutes before eating any food, drinking anything else, or taking any other oral medications
4. Swallow whole — do not split, crush, or chew

That's not complicated if your mornings are predictable. Wake up, take the pill with a small sip of water, shower, get dressed, then eat. Many patients report making it seamless — one reviewer on a public forum described setting an alarm at 4 AM, taking the pill, going back to sleep, and eating breakfast on a normal schedule. But it is a non-negotiable restriction. Even too much water can affect absorption. Coffee is off-limits during that window. If you take morning medications for blood pressure or thyroid, those need to wait too. For someone with a chaotic 6 AM household, that 30-minute window can feel like negotiating a treaty.

Foundayo: Take It and Move On

Foundayo's instructions are three words: take it daily. That's effectively it:

1. Once daily, any time of day
2. With or without food
3. No water restrictions
4. Swallow whole

No timing your coffee. No setting alarms at 4 AM. No rearranging your entire morning medication lineup. For people with unpredictable schedules, that simplicity is Foundayo's biggest selling point.

Why This Matters More Than You Think

Here's the uncomfortable truth about GLP-1 therapy: the best pill is the one you take correctly every day for a year or more. Adherence isn't a soft variable — it's the whole game. If you take the Wegovy pill with food because you forgot to fast, you've dramatically reduced absorption and potentially wasted a day's dose. That's not a hypothetical risk; it's the core design limitation of an oral peptide that needs an empty stomach to survive digestion.

Dr. Catherine Varney, the obesity medicine director at UVA Health, told NPR (April 2026) she wouldn't be surprised if patients on Foundayo lose more weight in real-world practice — not because the drug is inherently stronger, but because it's harder to mess up. When strict dosing rules cause even occasional non-compliance, the clinical trial gap between the two pills can narrow or disappear entirely.

This isn't an argument against the Wegovy pill. If your routine accommodates it, you'll get the full efficacy benefit. It's an argument for being honest with yourself about what “daily” actually looks like in your life.

Does the morning fast fit your routine? If yes, the Wegovy pill gives you the stronger data. If no, don't fight it — Foundayo was built for exactly that situation.

How Much Do Wegovy Pill and Foundayo Cost in 2026?

Both Novo Nordisk and Eli Lilly clearly timed their pricing to be as competitive as possible. Here's what each actually costs by dose, scenario, and coverage status — verified on April 4, 2026 from official manufacturer pricing pages.

Wegovy Pill — Price by Dose

• With commercial insurance + savings card: as low as $25/month
• List price (WAC): $1,349.02 for a 30-day supply
• Available through: NovoCare Pharmacy, 70,000+ retail pharmacies, Ro, GoodRx, Weight Watchers

Source: NovoCare pricing page and Wegovy.com, verified April 4, 2026.

Foundayo — Price by Dose

• With commercial insurance + savings card: as low as $25/month
• Medicare Part D: ~$50/month starting July 1, 2026
• List price (WAC): $649/month
• Available through: LillyDirect (now), broad pharmacy rollout underway

Source: LillyDirect pricing page and Lilly investor announcement, verified April 4, 2026.

What the Pricing Actually Means for You

The entry point is identical: $149/month for both at the lowest dose. At maintenance doses, both converge to roughly $299/month if you stay in the manufacturer's self-pay program. Here are the pricing details most comparisons skip:

The Wegovy pill's $149 deal on the 4 mg dose expires August 31, 2026. After that, the second-step dose jumps to $199/month. If you're starting now and plan to be cash-pay, that's worth knowing for your month-three budget.

Foundayo's $299 cap at the highest doses requires continuous enrollment in the Self-Pay Journey program. You must renew within 45 days of your previous fill. Miss that window, and the 17.2 mg dose goes to $349/month.

Foundayo's list price ($649/mo) is less than half of Wegovy pill's list price ($1,349/mo). This matters primarily if your insurance bases copay calculations on WAC. The out-of-pocket experience may look similar, but the underlying economics favor Foundayo for insurance negotiations.

If you're on Medicare Part D, Lilly says eligible individuals may be able to get Foundayo for ~$50/month as early as July 2026, though final plan participation may vary. Wegovy pill Medicare coverage is also expanding — check your specific formulary for both.

Ro (working with Novo Nordisk on the nationwide Wegovy pill launch) offers Wegovy pill starting at $149 for the first month through its Body program. The membership includes telehealth visits, ongoing clinical support, and medication management.

Side Effects: What to Actually Expect

Both medications are GLP-1 receptor agonists, so the side effect profiles overlap significantly. GI symptoms dominate the first few weeks and typically improve as your body adjusts.

Common Side Effects — Both Pills

Sources: Wegovy prescribing information and Foundayo prescribing information.

The Discontinuation Question

The ORION indirect comparison suggested that Foundayo has approximately 4x higher odds of patients stopping treatment due to any adverse event and 14x higher odds of stopping due specifically to GI side effects compared to the Wegovy pill.

But context matters: these figures come from an indirect cross-trial comparison (not head-to-head), funded by the company that sells the competing product. Real-world discontinuation patterns with two pills that launched weeks apart will take months to become clear. We'll update this section as post-market data accumulates.

In the ATTAIN-1 trial itself, Foundayo's side effects were described as mild to moderate and primarily gastrointestinal — consistent with any GLP-1 medication. The first few weeks are usually the worst, and most patients who make it past dose escalation report symptoms become manageable or resolve.

The Birth Control Warning You Need to Know

Foundayo's prescribing information includes a warning that it may reduce the effectiveness of oral hormonal contraceptives. Patients using birth control pills should talk to their prescriber about adding a non-oral backup method (like an IUD, patch, or condoms) for 30 days after starting Foundayo and after each dose increase.

The Wegovy pill does not carry this warning. If you're on oral contraceptives and don't want to deal with backup methods through a multi-month dose escalation, the Wegovy pill eliminates this variable.

Drug Interactions Most Pages Miss

Foundayo is a small molecule metabolized differently than the Wegovy pill, and its prescribing information includes specific interaction warnings:

• Strong CYP3A4 inhibitors (like ketoconazole, certain HIV medications): cap Foundayo's maximum dose at 9 mg
• Strong CYP3A4 inducers (like rifampin, certain seizure medications): should be avoided entirely with Foundayo
• Simvastatin: should not exceed 20 mg daily when taking Foundayo
• Other oral medications: Foundayo may affect absorption, though this is less restrictive than Wegovy's blanket 30-minute wait rule

The Wegovy pill's interaction profile is more straightforward — it's the same semaglutide molecule that's been prescribed as Ozempic since 2017, so the safety track record is much longer. If you're on multiple medications, run the full list past your prescriber before choosing either pill. But if you're on simvastatin or a CYP3A4-interacting drug, that specific detail could make the decision for you.

Most people tolerate both pills well after the initial adjustment period. The side effects are real but manageable — and they're the price of entry for a medication class that produces meaningful, sustained weight loss. If you've made it this far in your research, the side effects aren't what's stopping you. The question is which pill fits your life.

Does One Pill Protect Your Heart Better Than the Other?

Yes. Right now, this isn't even close.

The Wegovy pill carries an FDA-approved indication for reducing the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — in adults with established cardiovascular disease and either obesity or overweight. This comes from the landmark SELECT trial.

Foundayo does not have this indication. Cardiovascular outcome trials for orforglipron are ongoing, and they may eventually show similar benefits — but that data doesn't exist yet.

If you have established heart disease, a history of heart attack or stroke, or significant cardiovascular risk factors, this is currently a Wegovy-only benefit. Your cardiologist or prescriber may weigh this heavily.

Can You Actually Get These Pills Right Now?

Wegovy Pill — Available Now

The Wegovy pill was FDA-approved December 22, 2025 and launched across the U.S. on January 5, 2026. It's available through:

• 70,000+ retail pharmacies including CVS, Costco, and Walgreens
• Telehealth platforms: Ro (Novo Nordisk's official launch partner), LifeMD, Weight Watchers, GoodRx Care
• NovoCare Pharmacy — Novo Nordisk's direct-to-patient pharmacy
• Over 600,000 patients have started the Wegovy pill since launch

Foundayo — Launching Now

Foundayo was FDA-approved April 1, 2026. Current access:

• LillyDirect: accepting prescriptions immediately; free home delivery began April 6, 2026
• Retail pharmacies: broad availability expected shortly after launch
• Telehealth providers: expected to follow quickly, though specific platform availability is still rolling out

The Wegovy pill has a three-month head start in terms of pharmacy infrastructure, prescriber familiarity, and insurance coverage decisions. If speed-to-start matters, the Wegovy pill has a logistical edge.

What Ro's Process Looks Like for the Wegovy Pill

Ro launched Wegovy pill access through its integration with Novo Nordisk and is our recommended route for the Wegovy pill. Here's what to expect:

1. Complete a short online health assessment (takes about 5 minutes)
2. A licensed clinician reviews your information
3. If you're eligible, your prescription is sent to the pharmacy
4. Medication ships to your door or you pick up at a retail pharmacy

Ro's Body program includes ongoing clinical support, so you're not just getting a prescription and being left on your own. The membership is $45 for the first month and $145/month after, with medication billed separately based on the Wegovy pricing tiers listed above.

We mention Ro specifically because they've been live with the Wegovy pill since day one of the January 5 launch. That track record matters when you're starting a new medication.

What Real People Are Saying About These Pills

These medications are new enough that long-term patient reviews don't exist yet. But the early signal from patients, clinical discussions, and public forums is worth capturing — with the caveat that individual experiences vary and early adopters tend to skew enthusiastic.

On the Wegovy pill, the morning routine is the recurring theme in online patient communities. Some describe it as seamless — adapting by setting an early alarm, taking the pill, and going about their normal routine after the 30-minute wait. Others describe the fasting window as genuinely disruptive, especially when coffee is non-negotiable or other morning meds compete for that empty stomach. A common concern that surfaces repeatedly in patient forums: even excess water can affect absorption, which makes the dosing feel fragile.

On the convenience divide more broadly, the sentiment that keeps surfacing captures the decision perfectly: the best GLP-1 medication is the one you actually take consistently. That's not a throwaway platitude. For GLP-1 therapy — where the benefits depend on continuous daily or weekly use over months and years — it's the single most important variable.

What we haven't seen yet: real-world patient experiences with Foundayo, since it just launched. As those emerge over the coming weeks and months, we'll incorporate verified patient perspectives here.

Over 600,000 prescriptions for the Wegovy pill have been written in three months. That's not a clinical trial — that's real people, real prescribers, real results building in real time. If you've been considering an oral GLP-1, you're not early anymore. You're right on time.

Is There a Real Head-to-Head Trial?

No. And this is worth spending a moment on, because half the content on the internet right now doesn't label this clearly.

There is no head-to-head obesity trial comparing the Wegovy pill (oral semaglutide 25 mg) against Foundayo (orforglipron) in the same obesity population using the same study design. Here's what does exist, clearly labeled:

• OASIS 4 — Direct obesity trial for the Wegovy pill. Strongest evidence for the Wegovy pill in obesity. Published in NEJM.
• ATTAIN-1 — Direct obesity trial for Foundayo. Strongest evidence for Foundayo in obesity. Used for FDA approval.
• ACHIEVE-3 — Head-to-head trial of orforglipron vs oral semaglutide, but in type 2 diabetes patients, and using the lower Rybelsus 14 mg dose — not the 25 mg Wegovy pill dose.
• ORION — Indirect cross-trial comparison presented at OMA 2026, funded by Novo Nordisk. Found a 3.2% weight-loss advantage for the Wegovy pill. Useful directional data with acknowledged limitations.

When you read claims about one pill being definitively “better” than the other, trace it back to the source. On this page, we weight direct obesity evidence above everything else — and by that measure, the Wegovy pill's OASIS 4 data is currently the strongest in the oral GLP-1 category.

Can You Switch Between These Pills — or From Injections?

From Injectable Wegovy to Wegovy Pill

Yes, and it's the simplest transition. Both contain semaglutide. Per the Wegovy label, patients taking Wegovy 2.4 mg injection may switch to Wegovy 25 mg tablets — one week after discontinuing the injection, initiate 25 mg tablets once daily. Many patients are switching specifically to ditch the needle while staying on the same molecule they trust.

From Wegovy Pill to Foundayo (or Vice Versa)

Technically possible with a new prescription and prescriber guidance, but there's no published dose-equivalence protocol yet since both pills are so new. Your prescriber would likely restart you on Foundayo's lowest dose and escalate. The same applies in reverse. You cannot take both pills simultaneously — both labels warn against combining GLP-1 receptor agonists.

From Compounded Semaglutide to Either Pill

If you're currently using compounded semaglutide and want to move to an FDA-approved oral option, both pills are legitimate pathways. We have a detailed switching guide that covers the practical steps.

What About Zepbound or Mounjaro Users?

Foundayo is made by Eli Lilly — the same company behind Zepbound and Mounjaro. But Foundayo is a different molecule (orforglipron), not oral tirzepatide. It targets only the GLP-1 receptor, while Zepbound and Mounjaro target both GLP-1 and GIP receptors. If you're on Zepbound and getting strong results, switching to either oral GLP-1 would likely mean less weight loss.

What if Neither Oral Pill Is the Right Fit?

If you want the highest weight-loss ceiling and don't mind injections, the weekly injectables (Wegovy injection, Zepbound) still outperform both oral options. Injectable semaglutide produced ~17% weight loss in the STEP trials. Injectable tirzepatide (Zepbound) has shown up to ~22% in some trials. We cover all the injectable options in our comprehensive GLP-1 provider comparison.

If your primary concern is cost, and the $149–$299/month range is a stretch, there may be other options to explore. Our GLP-1 cost and savings guide walks through every route we've found.

If you're genuinely unsure about which GLP-1 format, medication, or provider fits, that's exactly what our matching quiz is built for. It takes 60 seconds and returns a personalized recommendation.

How We Verified This Page

We built this comparison from primary sources — not from other blogs or news summaries. Here's exactly what backs every claim:

• Efficacy data comes from the OASIS 4 trial (Wegovy pill, published in NEJM September 2025) and the ATTAIN-1 trial (Foundayo, from Lilly's FDA filing).
• Pricing was verified on April 4, 2026 by checking the official NovoCare pricing page (Wegovy), the official LillyDirect pricing page (Foundayo), Wegovy.com coverage information, and Ro's published Wegovy pill pricing.
• Dosing and safety information comes from the FDA-approved prescribing information for both Wegovy tablets and Foundayo tablets.
• Approval and availability dates were confirmed against FDA press announcements and official manufacturer launch communications.

What we update: Pricing is verified monthly. FDA status and availability are updated as changes occur. Trial data is updated when new published results become available.

What we don't claim: We do not claim these trials are directly comparable. We do not claim our affiliate partners are the only way to access these medications. We do not claim that either pill will produce specific results for any individual — the trial averages are population-level data, and your results will depend on your adherence, starting weight, metabolism, and other individual factors.

Source hierarchy: FDA prescribing information > published peer-reviewed trials > official manufacturer pricing pages > manufacturer press releases > news reporting. We clearly label when a data point comes from a company-sponsored analysis or an indirect comparison.

Frequently Asked Questions: Wegovy Pill vs Orforglipron

The Bottom Line

You searched Wegovy pill vs orforglipron because you wanted a straight answer. Here it is, one more time:

The Wegovy pill is the better pick for most people. Stronger obesity-specific weight loss data. An FDA-approved cardiovascular benefit. Three months of real-world adoption with 600,000+ prescriptions written. A proven molecule (semaglutide) with nearly a decade of safety data from its injectable form. If you can handle the 30-minute morning fast, it's the more complete package right now.

Foundayo is the better pick if your life doesn't bend to a strict morning routine. No food restrictions, no timing rules, no water limits. For shift workers, frequent travelers, busy parents, or anyone who's tried timed medication regimens and watched them fall apart — Foundayo is not the compromise option. It's the realistic one. And a pill you take correctly every day beats a “stronger” pill you take wrong three times a week.

Both cost the same at the starting dose. Both are FDA-approved. Wegovy pill is broadly available now. Foundayo prescriptions are being accepted, with shipping underway as of April 6.

The question isn't which pill is objectively better — it's which pill you'll actually take correctly for a year. And the fact that you're researching this carefully, reading a comparison this detailed, tells us something: you're serious about this. You're not looking for hype. You're looking for the right information to make a confident decision. You have it now. The next step takes less than five minutes.